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Abstract
Being HIV–1–PR an essential enzyme in the viral life cycle, its inhibition can control AIDS.
Because the folding of single domain proteins, like HIV–1–PR is controlled by local elementary
structures (LES, folding units stabilized by strongly interacting, highly conserved amino acids)
which have evolved over myriads of generations to recognize and strongly attract each other so
as to make the protein fold fast, we suggest a novel type of HIV–1–PR inhibitors which interfere
with the folding of the protein: short peptides displaying the same amino acid sequence of that of
LES. Theoretical and experimental evidence for the specificity and efficiency of such inhibitors are
presented.
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I. INTRODUCTION
HIV–1–PR is a homodimer, that is a protein whose native conformation is built of two
(identical) disjoint chains each of them made of 99 amino acids. Sedimentation equilibrium
experiments have shown that at neutral pH the protease folds according to a three–state
mechanism (2U → 2N → N2), populating consistently the monomeric native conformation
N [1]. The dimer dissociation constant (2N → N2) is kD = 5.8 µM at room temperature,
while the folding temperature of the monomer, i.e. the temperature at which the free energy
of the native monomeric state N is equal to that of the unfolded state U is Tf = 52.5C [2].
Monte Carlo simulations of the folding of three–state homodimers [3] indicate that after
the monomers have reached the native state N , they diffuse to find another folded monomer
to associate with. The same study also shows that in the stage U → N , each monomer
folds according to the same mechanism controlling the folding of single domain proteins.
This mechanism is reasonably well understood as a result, among other things, of extensive
lattice model studies as well as of all–atom off–latice Go¯–model simulations (cf. ref. [4] and
refs. therein). These studies revealed the central role played by few, strongly interacting
highly conserved, as a rule hydrophobic, amino acids. Mutations of these ”hot” amino
acids lead, in general, to denaturation [5]. It has been shown [6, 7] that, starting from
an unfolded conformation, folding proceeds following a hierarchical succession of events: 1)
formation of LES stabilized by the interaction among ”hot” amino acids lying close along
the polypeptide chain, 2) docking of the LES into the (post critical) folding nucleus, that is
formation of the minimum set of local contacts which brings the system over the major free
energy barrier of the whole folding process, 3) relaxation of the remaining amino acids on
the native structure shortly after the formation of the folding nucleus. Strong support for
the soundness of this hierarchical scenario is found in a number of circumstantial evidences
[8, 9, 10, 11, 12, 13, 14, 15].
The same model [6, 7] suggests that it is possible to destabilize the native conformation
of a protein with the help of peptides whose sequences are identical to those of the LES
of the protein [16]. Such peptides (p–LES) interact with the protein (in particular with
their complementary LES) with the same energy which stabilizes its folding nucleus, thus
competing with its formation.
One can mention two advantages of these non–conventional (folding–) inhibitors as com-
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pared to conventional (active site centerd–) inhibitors: I) their molecular structure is direclty
fixed by that of the target protein. One has thus not to design a molecule so as to optimize
its interaction with a given site of the enzyme, but just find which are the LES of the protein
to be inhibited. The design of the p–LES having been performed by evolution. In fact, like
the pair enzyme/substrate, pairs of complementary LES have evolved through millions of
years in order to learn how to recognize its partners as well as to avoid aggregation, II)
it is unlikely that the protein can develop drug–resistance through mutations as LES are
stabilized by hot amino acids.
The present paper is divided in two main parts. A theoretical one (Sections 2 and 3)
where the prediction of the model are presented, and an experimental one (Sect. 4), where
the properties of the designed inhibitor are tested.
II. FOLDING UNITS OF HIV–1–PR: LOCAL ELEMENTARY STRUCTURES
The first step to be taken in the design of an inhibitor of the HIV–1–PR following the
strategy discussed in the previous Section is to determine the LES of the target protein. In
other words, segments of the protein containing highly conserved residues. To this scope use
is made of evolution data input as well as model simulations.
A. Evolution
A measure of the degree of conservation of residues in a family of proteins is the entropy
per site S(i) = −
∑
σ pi(σ) ln pi(σ), where pi(σ) is the frequency of appearence of residue of
type σ at site i. Making use of a family of 28 uncorrelated proteins (i.e., displaying sequence
similarity lower than 25%) structurally similar to HIV–1–PR [17], the entropy S(i) was
calculated for all 99 sites of the monomers. From the result shown in Fig. 1(a) (continous
curve) it is observed that the most conserved regions of the proteins involve residues 24-33,
56-61 and 81-87. Note that the conservation of residues 25-27 is not unexpected in that they
build the active site of the protease.
Another important source of information concerning protected sites of the HIV–1–PR
stems from drug-induced mutations observed in vivo. The large production of virion in
the cell, coupled with the error prone reverse transcriptase enzyme, eventually leads to
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escape mutants. Mutations observed in the stretches of the HIV–1–PR mentioned above
are, as a rule, conservative mutations (e.g. L24I) [10, 18]. Less conservative mutations, e.g.
hydrophobic to hydrophilic, are absent from these structurally protected regions.
B. Model calculations: energetics
In order to become stable at an early stage of the folding process, LES must carry a
significant fraction of the total energy of the protein. We have calculated this quantity
making use of short all-atom molecular dynamics simulations in explicit water using GRO-
MACS software [19]. The calculation was performed at 295 K for 1 ns, during which the
protein fluctuates around its native conformation (the maximum RMSD being 11A˚). We
have followed the scheme described in ref. [20], calculating the average interaction energy
Bij between any pair of amino acids during the 1ns dynamics and extracting the eigenvalues
λn of the resulting matrix ‖ Bij ‖. The lowest energy state (λ1=-121.2 kJ/mol) displays a
large energy gap (i.e. -12.9 kJ/mol≈ 5kT ) with respect to the next eigenvalue, indicating
a core of strongly interacting amino acids [20]. We display in Fig. 1(b) the eigenvector
associated with the lowest energy eigenvalue, which highlights to which extent the different
amino acids participate to this core. The largest amplitudes involve residues 25–32, 57–65,
74–77 and 83–90. Regions 25–32, 57–65 and 83–90 overlap well with the conserved regions
mentioned above in connection with Fig. 1(a).
Another way of representing the interaction matrix ‖ Bij ‖ is to consider the interaction
between fragments S1 = (13 − 21), S2 = (24 − 34), S3 = (38 − 48), S4 = (50 − 55),
S5 = (56 − 66), S6 = (67 − 72), S7 = (74 − 78), S8 = (84 − 94). As can be seen from
Table I, the corresponding 8× 8 energy map is essentially codiagonal, the associated energy
of the interacting chain segment being −1751 kJ/mol as compared to the MD simulation
native energy −2533 kJ/mol. In other words, the S1 − S8 representation of the folded
monomer accounts for ≈ 70% of the calculated native conformation energy. In particular,
the interaction between fragments S2, S5, S7 and S8 is stabilized by −796 kJ/mol equal to
32% of the native conformation energy. Of this energy 20% (= −503 kJ/mol) corresponds
to the internal energy of the four fragments, while 12% (= −293 kJ/mol) corresponds to
the summed interaction energy between fragments.
In keeping with the above results the S2, S5, S7 and S8 segments qualify as LES (folding
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units) of each of the two monomers of the HIV-1-PR dimer, LES which form in their native
conformation the (post critical) folding nucleus (FN). It is interesting to note that drug
induced mutations in the amino acids belonging to these LES (L24I, D30N, L33F, L63V,
I64V, V77I, V82A, I84D, N88D and L90M [18, 21]), lead to a folding nucleus energy equal
to -1500 kJ/mol, as compared to -796 kJ/mol for the wild type sequence FN, that is to
increase of almost a factor of 2 in the stability of the system.
C. Further evidence
Wallqvist and coworkers[10] investigated the HIV–1–PR molecule for the occurence of
cooperative folding units that exhibit a relatively stronger protection against unfolding than
other parts of the molecule. Unfolding penalities are calculated forming all possible com-
binations of interactions between segments of the native conformation and making use of a
knowledge–based potential. This procedure identifies a folding core in HIV–1–PR comprising
residues 22–32, 74–78 and 84–91, residues that form a spatially close unit of a helix (84–91)
with sheet (74–78) above another β–strand ((22–25), containing the active site residues D25,
T26 and G27) perpendicular to these elements.
Making use of a Gaussian network model, Bahar and coworkers [22] have studied the
normal modes about the native conformation of HIV–1–PR. ”Hot” residues, playing a key
role in the stability of the protein, are defined as those displaying the fastest modes. In this
way regions 22–32, 74–78 and 84–91 are identified as those forming the folding core of the
protein. These regions match with those displaying low experimental Debye-Weller factors,
that is low fluctuations in the crystallographic structure.
Calculation of ϕ–values by means of Go¯–model simulations performed by Levy and
coworkers [23] have located a major transition state where only regions 27–35 and 79–87 are
structured. The protein then reaches the native state, overcoming another minor transition
state, and subsequently dimerizes into the biologically active structure.
Cecconi and coworkers [24] have calculated the stability temperatures associated with
each contact of the protease, again making use of a Go¯–model. They find that key sites to the
stability of partially folded states, that is those displaying the lowest stability temperatures,
are 22, 29, 32, 76, 84 and 86.
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D. Dynamics of contact formation
To directly investigate the folding mechanism of the HIV–1–PR monomer, use is made of
a simplified model which has proven useful to account for the folding properties of a number
of small, single–domain proteins [25]. The model pictures each amino acid as a spherical
bead, making inextensible links with the rest of the chain. Each pair of amino acid interacts
through a modified Go¯–contact potential [26]
U({ri}) =
∑
i<j
Bij∆(|ri − rj|), (1)
where ri is the coordinate of the ith amino acid, ∆(|ri − rj|) is a contact function which
assumes the value 1 if the ith and jth residues are closer than 6.3A˚ and zero otherwise, Bij
being the energy matrix elements defined in Sect. 2b. Moreover, each amino acid displays
a hard core of 3.8A˚.
Equilibrium Monte Carlo simulations of the HIV–1–PR monomer provide free energy
landscapes as a function of the fraction qE of native energy of the protein. The free energy
at T = 300K, shown in Fig. 2(a) with a solid curve, displays two major wells, corresponding
to the unfolded and the native states. The grey beads mark conformations met during the
sampling, and their position along the y–axis indicate the associated RMSD (cf. scale on the
left y-axis). Note that the native well is quite broad, ranging from qE = 0.75 to qE = 0.95
and from an RMSD of 3 to 7 A˚. Also the free energy barrier to the unfolded state is
rather small, being about 18 kJ/mol (≈ 7 kT ). These data indicate a two–state transition
characterized by a weak degree of collectivity. To be noted that in the present calculations we
only considered the monomeric form of the protein. Dimerization can increase the stability
and the collectivity of the system.
Making use of the same model it is possible to run dynamical simulations, starting from
random conformation and following the folding to the native state. The overall dynamics
can be followed through the plot of [qE ](t), that is the fractional native energy as a function
of time, averaged over 100 independent runs. The result is displayed as a solid curve in
Fig. 2(b), indicating an exponential process of characteristic time τ = 2.9 · 10−7s, consistent
with the two–well picture. The model provides also information about the formation of each
contact, through the probability pij(t) that the contact between residues i and j is formed
at time t. A number of native contacts are stabilized early (sub–nanosecond time scale)
6
following an exponential dynamics. This is the case for contacts belonging to S2 (25–28)
and in particular to S8 (e.g. contacts 86–89, 87–90, 89–92, 90–93). Contacts between residues
which are far along the chain are formed later, following a non–exponential dynamics, which
indicate that their formation is dependent on some other event. The earliest involve the
interaction between fragments S5 − S7 and S2 − S8 which take place after an average time
of few and of tens of ns, respectively. As an example we display in Fig. 2(b) the formation
probability of the contact 31-89 as a function of time.
In Fig. 2(c) is summarized the hierarchy of formation of native contacts of HIV–1–PR,
the different gray levels corresponding to different time scales, while in Table II are listed
the parameters associated to the selected contacts. The picture that emerges is that local
contacts within fragments 83–93, between residues 25–28 and in the beta–hairpin 42–58 form
first. Then the beta–turns 15–18 and 65–70, again built of local residues. The next event is
the assembly of the nucleus involving fragments 22–34 and 83–93, which is further stabilized
by the contribution of the strongly–interacting bend 77–83. Finally, the rest of the residues
come to place.
Summing up, the model suggests that LES are built of residues which lie in the regions
83–93 and 22–34. This essentially agrees with the indirect indications provided by the
studies of Levy and coworkers [23], which indicate the formation of regions 27–35 and 79–87
as determinant for the folding of the protein. The stabilization core [27] is somewhat larger
(cf. Sect. II B), involving, besides residues 84–93 and 22–34, also the regions 56–66 and
74–78.
From the above discussion one can conclude that peptides p–S2 and p–S8 are the most
likely candidates as folding inhibitors of the HIV–1–PR monomer. Because S8 is well struc-
tured (it builds 10 internal contacts and an α-helix turn), while S2 has little internal struc-
ture, we shall select p–S8 as the best candidate for a non–conventional inhibitor. It is
expected that peptides p–S8 will efficiently attach to the S2–LES, thus blocking the forma-
tion of the folding nucleus or, in the case the protein is already folded, by profiting favourable
fluctuations around the native conformation, to come into contact with the S2–LES thus
blocking the return of the monomer to the original native conformation.
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III. INHIBITION OF THE FOLDING OF THE HIV–1–PR
Within the framework of the Go¯ model discussed above, Monte Carlo simulations were
carried out for a system composed of a single 99mer and a number (from 1 to 5) of p-S8
peptides, placed inside a box of side of 100 A˚ with periodic boundary conditions.
In Fig. 3(a) the resulting free energy of the protein as a function of qE is displayed. The
presence of p–S8 peptides has a number of effects: a) it broadens the minimum associated
with the native conformation, b) it lowers by ≈ 10kJ/mol the free energy of the minimum
associated with the unfolded state, c) it lowers by about the same amount the free energy of
the maximum of the barrier separating the two minima (transition state). These effects are
associated with a decrease of the relative population of the native state from 0.98 to 0.78 in
the case of 3 peptides and to 0.52 in the case of 5 peptides. Because the above results were
obtained from calculations which describe the system at equilibrium they apply equally well
to situations in which one starts with the monomer in the state N or in state U.
To test the validity of these results, we have repeated the simulations using peptides
corresponding to fragments of the protease monomers different from the LES, but having
a similar number of amino acids. It is found that e.g., fragments 9–19 and 61–70 do not
have any significant effect on the free energy of the native state (cf. Fig. 3(b)). This result
testifies to the fact that the denaturing effect observed in the results shown in Fig 3(a) is
due not to some unspecific interaction between the peptides and the protein, but to the very
choice of LES–mimicking peptides.
To further clarify the mechanism which is at the basis of the results shown in Fig. 3(a),
we display in Fig. 4(b) a snapshot of the simulation carried out with 3 peptides. It is
seen that one of the p–S8 peptides has built (strong) contacts stabilizing the folding nucleus
of the protein. Consequently, the state corresponding to the correctly folded monomer
(Fig. 4(a)) and to the state in which the peptide binds to the partially folded protein have
similar energies but very different free energies. In fact, the main difference between the two
conformations displayed in Fig. 4(a) and 4(b) is entropic: while the partially folded protein
has a much larger entropy as compared to the folded protein (which essentially is in a single
conformation), the complexed state is penalized by the entropy decrease associated with the
binding of a single peptide, decrease which can be reduced at will by increasing the number
of peptides.
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Consequently, whatever the folding entropy cost of binding a p–S8 is, there exists a
concentration of peptides which makes the complexed, partially–unfolded state favourable.
In the case of the present simulations, a concentration of peptides equal to few times that
of the protein seems to be adequate to consistently destabilize the protease.
We have also analyzed the effect pointlike mutations [35]on the HIV–1–PR have on the
inhibitng ability of p–S8 peptides. Mutations on sites not belonging to LES have little or
no effect on the stability of the protease, but at the same time do not affect the inhibitory
action of p–S8. For example, mutations on site 73 cause the protease to decrease its stability
at 300 K from 98% (observed for the ”wild–type” sequence) to 97%, the effect of 3 p–S8
peptides leading to a decrease of this stability from 97% to 32% (to be compared with the
98% to 52% decrease observed in the case of the ”wild–type” sequence). Mutations in sites
belonging to the LES of the HIV–1–PR, on the other hand, cause destabilization of the
native state of the protease, shifting the equilibrium distribution of the order parameter qE
towards lower values. For example, mutation in site 34 causes the stability of the protease
to diminish to 64% (from the value of 98%).
IV. SPECTROPHOTOMETRIC MEASUREMENTS
Following the theoretical predictions discussed above, we have investigated the inhibitory
properties of the peptide of sequence NIIGRNLLTQI (p–S8 ≡ 83–93) by means of a spec-
trophotometric assay as described in ref. [28] and making use of ultraviolet circular dichroism
[29].
A. Materials and methods
Recombinant HIV-1-Protease, expressed in E. Coli (Sigma Cat. no. P7338) [30, 31]
contained five mutations to restrict autoproteolysis (Q7K, L33I, L36I) and to restrict cys-
teine thiol oxidation (C67A and C95A). The enzyme was stored at (-70C as solution with
concentration 25µg/63µL in dilute HCl, (pH=1.6) ). A chromogenic substrate for HIV-
1-PR (Sigma Cat. no. H5535) (with sequence Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2)
was obtained as a 1 mg desiccate, diluted with 0.1 ml of DMSO, and stored at -20C. Pro-
tease assisted cleavage between the Nle and the Phe(NO2) residues of substrate entails a
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blue-shift of the absorption maximum (277 nm to 272 nm). It can be adequately moni-
tored observing the continuous decrease of absorbance at 310 nm [28]. A regression of the
absorbance at 300 nm against substrate concentration allows to estimate the extinction co-
efficient of the whole substrate (S = 6300 ± 1600 (mol cm)−1). Moreover, the absorbance
at 300 nm after complete peptidolysis allows to determine a differential extinction coefficent
(= 1500 ± 250 (mol cm)−1) between the whole substrate and the cleaved products. This
compares well with a difference of extinction coefficient at 310 nm between the cleaved and
the complete substrate of 1200± 100 (mol cm)−1, reported in ref. [28].
Inhibitor peptide (peptide p–S8) from the primary sequence of the HIV–1–PR wild type
(PDB code 1BVG) were synthesized by solid phase synthesis (Primm, San Raffaele Biomed-
ical Science Park, Milan) with acetyl and amide as terminal protection group and was
estimated to be > 95% pure by analytical HPLC after purification. After that 1 mg of
inhibitor peptide was dissolved in 100 µl of DMSO, 4 µl of this solution were then diluted
with 16 µl of DMSO and 180 µl of the buffer used for assay. The obtained solution (150 µM
of peptide p–S8) was used for the experiments.
The buffer was prepared by adding 0.8 mM NaCl, 1 mM EDTA and 1 mM dithiothreitol
to a 20 mM phosphate buffer (pH 6). Other peptides displaying a sequence equal to that
of selected fragments of the protease, but not belonging to any LES, as well as another
peptide displaying a random sequence, were also used in the same way as peptide p–S8.
The sequences of these control peptides are QILIEICGHK and PLVTIKIGGQL correspond-
ing to fragments 61-70 and 9-19, respectively, of the HIV-1-PR sequence, as well as the
LSQETFDLWKLLPEN sequence, which is not related in any way to the protease. We will
call these peptides K1, K2 and K3, respectively. To be noted that peptide K2 is rather
hydrophobic and only > 70% purity could be achieved.
Each measure was performed recording the absorbance at 300 nm (4.13 eV) in a standard
UV-vis spectrophotometer (Jasco V-560). The sample had a total volume of 70 µL in
Spectrosil Far UV Quartz (170-2700 nm) cuvettes (3.3 mm optical path). The sample in
the cuvette was exposed to a constant temperature (37 ± 0.05C) provided by continuous
circulation of water from a waterbath to the cell holder via a circulation pump.
After proper thermal stabilization of the substrate dissolved in the buffer (pH 6), the ab-
sorbance at 300 nm was recorded. We performed 6 measures spanning a range of substrate
concentrations from 50 µM to 250 µM . The reaction was initiated by adding 2.78 µg of
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enzyme and recording the asbsorbance decrease at 300 nm for 1200 sec. In all the reported
measures the enzyme has thus a nominal concentration of 1.8 µM . Since, to our knowl-
edge, no accurate measure has been published of the dimerization constant of HIV–1–PR
at pH=6.0, it is difficult to estimate precisely the active site concentration in our assay. It
should however be noted that the active site concentration only affects the estimation of
kcat, and has no influence over the enzyme-inhibitor dissociation constants.
The assessment of the enzyme activity in presence of the inhibitor peptides followed a
similar routine: the enzyme and the peptide (whose concentration are in a ratio 1:3) were
incubated together for approximately 1 min and then added to the substrate. In all the
reported measures the final concentration of inhibitor was [I0] = 5.4 µM . The asbsorbance
decrease at 300 nm was recorded for 1200 sec.
Ultraviolet CD spectra were recorded on a Jasco J-810 spectropolarimeter in nitrogen
atmosphere at room temperature using 0.1 cm path-length quartz cell. Each spectrum was
recorded between 260-200 nm. The data were collected at a rate of 10 nm/min with a wave-
length step of 0.2 nm and a time constant of 2 s. The spectra were corrected with respect to
the baseline and normalized to the aminoacidic concentration. The protein and the peptide
were dissolved in a 20 mM phosphate buffer with 0.8 M NaCl at the same concentration used
for the activity assays. The CD spectra were analyzed in terms of contribution of secondary
structure elements [29] using the K2D method based on comparison with CD spectra of
proteins and peptides with known secondary structure.
B. Results
In order to provide a quantitative measure of the enzymatic activity of HIV-1-PR and
the inhibitory mechanism of the designed peptides, we have performed a Michaelis-Menten
analysis of the data reported in Fig. 5(b), measuring the initial reaction velocity v0 at
different substrate concentrations (cf. Fig. 5(a)). We obtain an estimate of the dissociation
constant KM for the uninhibited-enzyme/substrate complex (curve (2) of Fig. 5(b)) of
670 ± 860 µM . The maximum velocity of the reaction vmax results 0.40 ± 0.52 µM/s,
corresponding to a catalitic rate kcat = 0.25± 0.28s
−1. Note that the order of magnitude of
these results compares well with those reported for the same substrate in ref. [28], that is
KM = 280 ± 100µM and kcat = 7.3µM/s. The apparent dissociation constant K
′
M of the
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inhibited reaction is 332± 191µM , the maximum velocity being vmax = 0.026± 0.011µM/s
(cf. curve (1) of Fig. 5(b)). The fact that the value vmax changes in presence of the inhibitor
while that of K ′M remains within the experimental error of KM suggests that the inhibition
is compatible with a non-competitive scenario [32], in which the inhibitor can bind to the
free enzyme with a dissociation constant KI or to the substrate-enzyme complex with a
dissociation constant K ′I not significantly different from KI . The results shown in Fig. 5(a)
lead in fact to the values KI = 380± 810nM and K
′
I = 180± 234nM . The caveats and the
physical meaning of the interpretation of Fig. 5(a) in terms of a classical mixed models will
be examined in the next section.
We note that the large errors in the estimate of the kinetic parameters are due to the
small number of points recorded. An alternative method to determine the value of these
parameters involves the fitting of the data with the analytical solution of the Michaelis-
Menten kinetic [33], solution which can be written in terms of the reduced concentation
S ′ = S/KM as: [S
′](t) = W ([S ′0]exp(−kt + [S
′
0])), W being Euler’s Omega function and
k = vmax/KM .
Using a nonlinear fit to the data with the above expression one can obtain a more robust
estimate of both KM and vmax using the complete time-dependence of the concentration
of free enzyme, expressed as a function of the measured absorbance as [S](t) = 1/[A(t) −
A(∞)]/δǫ. In particular, using this method on curve (2) of Fig. 5(b), we have been able to
determine the kinetic values of the protease–substrate reaction obtainingKM = 656±320µM
and kcat = 0.49±0.08 s
−1. These values characterize more accurately the enzymatic process
than the values obtained from the analysis reported in Fig. 5(a).
We have repeated similar measures using this time the control peptides K1, K2 and K3
instead of peptide p–S8, and found no appreciable variation in the kinetic parameters with
respect to the uninhibited case (cf. curve (3) and (4) of Fig. 5(b)). In the presence of peptide
K1 or K2 the reaction displayed initial velocities v0 = 0.051µM/s and v0 = 0.049µM/s,
respectively, essentially identical to the value of v0 obtained from the global fit to the curve
(2) of Fig. 5(b).
The conformational properties of the inhibited protease have been investigated by means
of UV circular dichroism experiments. The CD spectrum of the protease (cf. Fig. 6)
under the same conditions used for the activity assay indicate a beta-sheet content of 79%,
consistent with the beta character of the native conformation [17]. The CD spectrum of
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the solution of protease plus p–S8 inhibitor, at the same concentrations and under the same
conditions as those of the activity assay, shows a loss of beta–structure (to a beta–sheet
content value of 45%), indicating that the protein is, to a large extent, in a non-folded
conformation. These numbers compare well with those predicted by the model calculations
(cf. caption to Fig. 4).
C. Discussion
The results described above show that the p–S8 peptide inhibits the activity of the HIV–
1–PR, interefering with the native character of its equilibrium state. Although a Lineweaver-
Burk plot like that displayed in 5(a) is usually interpreted in terms of a non-competitive
kind of inhibition, it can also describe the case of a irreversible binding of the inhibitor to
the enzyme [32]. In fact, in a reaction of the kind (where I ≡p–S8)
E + S
k+S
⇄
k
−S
ES
kcat→ P
+
I
k+I
⇄
k
−I
EI
(2)
where the rates k+I and k−I are much smaller than k+S and k−S, one can consider the
concentration [EI] as constant on a time scale smaller than (k−I)
−1, and given by [EI] =
(k−I/k+I)([E]0 − [EI])[I]0. In this context, irreversibility means that on the time scale
relevant for the experiment the dissociation of EI into E and I is negligible. The concentration
of enzyme available to the equilibrium with substrate is then, on this time scale, [E]0− [EI].
This leads to a Michaelis-Menten equation identical to that associated with non-competitive
inhibition, of the form
v0 =
[S]0[E]0
(
1 + [I]0
kI
)
−1
kcat
[S] +KM
(3)
where we have set ki = k−I/k+I . Note that the difference between the irreversible scenario
and the reversible competitive case is that, in the former, [EI] is proportional to [E0] while
in the latter [EI] is proportional to the free enzyme concentration [E]. Such irreversible
scenario is not unexpected in the case of folding inhibitors, where the inhibitor binds tightly
to the enzyme (as tight as the interactions which stabilize the protein), the unfolding rate
being of the order of 10−2s−1 [34], giving rise to a value of (k− I)−1 of the order of minutes.
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V. CONCLUSIONS
The peptide p–S8 (≡83N, 84I, 85I, 86G, 87R, 88N, 89L, 90L, 91T, 92Q, 93I) displaying
a sequence identical to that of the S8 LES of each of the two identical chains forming the
HIV–1–PR homodimer is found to be a highly specific and likely quite efficient inhibitor
(KI = 380 ± 810 nM) of the folding of the 99mers, and thus of the whole enzyme. A
remarkable property of this inhibitor is that it is unlikely that it would allow for escape
mutants. In fact, the only mutations which will prevent p–S8 from acting are expected to
involve protein denaturation.
Obvious disadvantages of the present design are the length and the peptidic character of
the inhibitor, because it is not clear how to prevent the degradation by cellular enzymes.
Consequently, there are two clear tasks lying ahead. One, to investigate whether the short-
ening of p–S8, by leaving out some residues either at the beginning or at the end (or both),
lead to peptides which still inhibit folding with similar specificity and effectiveness as p–S8
does. The second is to develop molecules mimetic to p–S8 or eventually to shorter peptides
derived from p–S8.
We conclude by suggesting that the strategy employed to design p–S8, being universal,
can be used to design inhibitors of the folding of other target proteins.
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FIG. 1: a) The entropy per site of proteins structurally similar to the HIV–1–PR monomer (pdb
code: 1BVG). The solid line indicates the entropy function calculated over 28 proteins displaying
sequence similarity lower than 25% with the HIV–1–PR, while the dashed line is associated with
462 proteins irrespective of sequence similarity. b) The components of the eigenvector associated
with the lowest eigenvalue of the interaction matrix between amino acids [20].
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FIG. 2: a) The free energy of HIV–1–PR monomer as a function of the relative energy (order
parameter) qE (black curve) and the values of RMSD sampled during the simulation (gray dots) at
T = 300K; b) The formation probability of the native conformation (solid curve), the probability
p87−90(t) (dashed gray curve) and the probability p31−89(t) (dotted gray curve), displayed as a
function of time; c) Contact map of the HIV–1–PR, the different gray levels being associated
with to different values of the average stabilization time. Darker symbols are formed in 10−10s
while lighter symbols in 10−7s. The dynamics is simulated by mean of a dynamical Monte Carlo
algorithm and the discrete time step is expressed in terms of time units by setting the simulated
diffusion constant of the protein equal to 10−7m/s2.
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FIG. 3: The free energy profile of the HIV–1–PR monomer (solid curve) and of the system composed
of the monomer plus 3 (dashed) and 5 (dotted) p–S8 peptides, as a function of the relative native
energy qE. The temperature at which the simulations were carried out is 300 K. b) The free energy
profile of the monomer alone (solid curve) and of the system composed of 3 peptides corresponding
to the fragments 9–19 (dotted curve) and 61–70 (dashed curve).
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FIG. 4: a) Native conformation of each monomer which build the HIV–1–PR dimer, based on
the NMR conformation of ref. [17]. b) Snapshot of the sampling of the system composed of the
protease and 3 p–S8 peptides. The protein has been drawn in light grey and the S2 and S8 LES
explicitely marked in dark grey. The p–S8 peptides are shown in black. The ratio of contacts
forming beta structure is 56% for the native conformation shown in (c), and decreases to 43% with
3 peptides (cf. (d)) and to 29% with 5 peptides.
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FIG. 5: a) The Lineweaver-Burk plot associated with the protease (empty circles) and the protease
complexed with the inhibitor p–S8 (filled squares). The dashed lines are the linear fits to the
experimental points. The initial velocities v0 are expressed in terms of absorbance/s, while the
substrate concentration [S] is in mM. b) The enzymatic kinetics of the inhibited protease (1), of
the protease alone (2), of the protease together with control peptides K1 (3) and K2 (4) , measured
as change in absorbance of the chromogenic substrate as a function of time. All the curves have
been measured at [S0] = 125mM , and have been shifted along the y-axis in order to be easily
inspected.
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FIG. 6: The circular dichroism spectrum of the protease (solid curve) and of the solution composed
of the protease and p–S8 peptide (dashed curve) in the ratio 1:3.
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